新华制药：第三季度归母净利润3246.42万元，同比下降58.74%

Core Insights - The company reported a revenue of 2.124 billion yuan for Q3 2025, representing a year-on-year growth of 6.10% [1] - The net profit attributable to shareholders decreased to 32.4642 million yuan, down 58.74% year-on-year [1] - Basic earnings per share for Q3 2025 were 0.05 yuan [1] Financial Performance - For the first three quarters of 2025, the company achieved a total revenue of 6.763 billion yuan, reflecting a slight year-on-year increase of 0.42% [1] - The net profit attributable to shareholders for the first three quarters was 256 million yuan, which is a decline of 25.53% compared to the previous year [1] - Basic earnings per share for the first three quarters were 0.37 yuan [1]